Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1 (allogeneic engineered T-cells) in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Next Previous
Trial Profile

A Phase 1, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1 (allogeneic engineered T-cells) in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UCARTCS 1 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms MELANI-01; MUNDI-01
  • Sponsors Cellectis

Most Recent Events

  • 04 May 2023 Status changed from recruiting to discontinued, according to a Cellectis media release.
  • 04 May 2023 According to a Cellectis media release, To optimize its resources, the Company decided to focus its development efforts on the BALLI-01, AMELI-01 and NATHALI-01 studies and therefore to stop enrollment and treatment of patients in the MELANI-01 study.
  • 03 Mar 2022 According to a Cellectis media release, the company is currently enrolling patients at Dose Level 1 (DL1) with FC preconditioning regimen.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top